Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...

Semaglutide, which is traditionally a treatment for type 2 diabetes, was given to participants who had been diagnosed with a ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Researchers chose to investigate semaglutide as a potential treatment because this class of drug has previously been shown to reduce fat and liver scarring for people with MASH. Between 2021 and ...